7 completed, 1 recruiting. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 7, Recruiting 1 |
Follow Topical corticosteroid: new trials by email Literature Review of Topical corticosteroid trials Research Report on Topical corticosteroid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis 611, Placebo, Topical corticosteroid - Dermatitis, Atopic, Eczema, Atopic | Phase 3 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 417 | 2024-09-23 | 2026-09-17 |
| Parasitic Ulcer Treatment Trial Polyhexamethylene biguanide (PHMB), Topical corticosteroid, Topical placebo - Acanthamoeba Keratitis | Phase 3 | Recruiting | Jeremy Keenan, MD, MPH | 232 | 2024-07-01 | 2026-10-01 |
| A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis Placebo, Lebrikizumab, Topical Corticosteroid - Atopic Dermatitis | Phase 3 | Completed | Eli Lilly and Company | 301 | 2024-04-24 | 2026-10-16 |
| A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis Lebrikizumab, Placebo, Topical Corticosteroid - Dermatitis, Atopic, Dermatitis | Phase 3 | Completed | Eli Lilly and Company | 286 | 2021-03-10 | 2023-08-23 |
| Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. Lebrikizumab, Placebo, Topical Corticosteroid - Atopic Dermatitis | Phase 3 | Completed | Eli Lilly and Company | 228 | 2020-02-03 | 2022-05-09 |
| A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis Baricitinib, Placebo, Topical corticosteroid - Atopic Dermatitis | Phase 3 | Completed | Eli Lilly and Company | 516 | 2019-05-24 | 2026-08-05 |
| A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis Baricitinib, Topical corticosteroid, Placebo - Atopic Dermatitis | Phase 3 | Completed | Eli Lilly and Company | 329 | 2018-11-16 | 2020-08-11 |
| A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable Baricitinib, Placebo, Topical corticosteroid - Atopic Dermatitis | Phase 3 | Completed | Eli Lilly and Company | 463 | 2018-05-15 | 2024-05-14 |
Dermatitis, Atopic (7) · Eczema (5) · Dermatitis (2) · Skin Diseases (2) · Acanthamoeba Keratitis (1) · Corneal Ulcer (1) · Skin Diseases, Genetic (1)
Eli Lilly and Company (6) · Jeremy Keenan, MD, MPH (1) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (1)
Germany (4) · Japan (4) · Poland (4) · Austria (3) · Brazil (3) · Spain (3) · United Kingdom (3) · Argentina (2) · Australia (2) · China (2) · France (2) · India (2) · Italy (2) · Russia (2) · South Korea (2)
Gerami Seitzman, MD (1) · Jeremy Keenan, MD, MPH (1)
PMID 33826132, PMID 36255569, PMID 33001140, PMID 33899152, PMID 34275122, PMID 36630140, PMID 36749121, PMID 39442013, PMID 39522957
2018 (2), 2017 (1), 2019 (1), UG1EY033284 (1)